Zydus Lifesciences Limited · NSE:ZYDUSLIFE

Zydus Lifesciences — Cadila Healthcare — Investor Presentation (August 2014)

17 slides from Zydus Lifesciences's investor presentation, August 2014

  1. Slide 1: Cadila Healthcare Limited Investor Presentation

    Cadila Healthcare Limited Investor Presentation August 2014

  2. Slide 2: Well integrated pharma player with global footprints

    Well integrated pharma player with global footprints >60 years $ 1 bn + ~ 7% of sales Operational Global Revenues Spent on R&D annually experience 20+ mfg. sites >20% CAGR 1st Indian Company In Net Worth and Net To discover & develop Producing >14 Profits an NCE in-house : bn pills annually (FY ‘09

  3. Slide 3: History of achieving milestones consistently

    History of achieving milestones consistently 35 fold growth in sales over last 19 years… …with significant external recognition CNBC – TV 18 India innovator Award 2013 Economic Times Emerging Rs. 200 cr. Company of the year 2010 in 1995 3

  4. Slide 4: Key businesses for our journey Beyond the Billion

    Key businesses for our journey Beyond the Billion Zydus Established home Future home New Technology Other Businesses markets markets businesses ▪ India formulations ▪ Brazil ▪ EU ▪ Biosimilars ▪ US formulations ▪ Mexico ▪ Emerging markets ▪ Vaccines ▪ Wellness ▪ NCEs ▪ Animal Health ▪ APIs ▪ JVs & a

  5. Slide 5: India formulations

    India formulations Aspirations Market size* : Rs. 775 bn+ Market growth* : 7%  Maintain strong leadership position in key areas – CVS, Zydus size** : Rs. 33.3 bn+ GI, respiratory, female healthcare, dermaceutical. Market Share* : 4.3% Zydus growth** : 8%  Continue to be one of the significant cont

  6. Slide 6: US formulations

    US formulations Market size* : ~$ 50 bn Aspirations Market growth* : 10%+ Zydus size** : ~ $ 366 mn  Be amongst the top 10 generic cos. in US with Zydus growth** : 32% continued strong focus on customer needs  One of the significant contributors to revenues and profits 33%+ CAGR in Sales (Last 5 y

  7. Slide 7: Brazil

    Brazil Market size* : ~ $ 18 bn Aspirations Market growth* : 12-14% Zydus size** : Rs. 2,353 mn  To establish strong base with aggressive product launches Zydus growth** : -1% Strengths to be leveraged  Presence in branded generics and generic generics segments with a continued focus on brand buil

  8. Slide 8: Mexico

    Mexico Market size* : ~ US$ 10 bn Aspirations Market growth* : 2-3% Zydus size** : Rs. 109 mn  To establish strong base with aggressive product launches. Strengths to be leveraged  Focused segments (Branded) – CNS, metabolic disorders and respiratory  Building product pipeline from India – 35+ fi

  9. Slide 9: Other Global Markets

    Other Global Markets Aspirations : To be amongst the leading players in these generics markets EU  8th largest in France, among top 20 in Spain Mkt. Size* : ~$ 6.5 bn  Expansion through new products : launched 115+ molecules in France (France + Spain Gx) and 80+ molecules in Spain so far (incl. se

  10. Slide 10: Other Businesses

    Other Businesses Wellness Aspirations : To create niches in wellness space through innovation  Leadership in sugar substitutes (~93% market share) and peel-off and scrub range for skin-care in India Zydus Size **:  Continuous thrust on new product launches with launch of several Rs. 4,296 mn produ

  11. Slide 11: Joint Ventures and Alliances

    Joint Ventures and Alliances Aspirations : Value creation through win-win alliances and be a partner of choice Zydus Takeda JV Zydus Hospira JV  State-of-the-art mfg. facility for APIs of  State-of-the-art cytotoxic facility approved Nycomed by leading authorities like MHRA, USFDA,  Commissioned

  12. Slide 12: Biosimilars and Vaccines

    Biosimilars and Vaccines Aspirations : Leverage technological edge to unlock substantial value and create pillars for future growth. Strengths to be leveraged Biosimilar pipeline Pre- Regulatory Mktg. Biosimilars Product Indication Cloning Process Devp. Clinical Permissio Clinical Devp. Authori-  D

  13. Slide 13: NCE research

    NCE research Aspirations : Add more NCEs in pipeline to drive towards becoming a research based pharma co. by 2020 Key strengths NCE Pipeline  State-of-the art Lead Pre- research facility Drug clinical Project Target Indication optimi- IND Phase I Phase II Phase III NDA Discovery Develop-  Capabil

  14. Slide 14: World class infrastructure to support growth journey

    World class infrastructure to support growth journey Formulations Mfg. Oral Solids (India) Oral Solids Other dosage forms  Ahmedabad (USFDA ) (outside India) (India)  Baddi (USFDA)  US (Nesher Pharma –  Transdermals – controlled substances) Ahmedabad SEZ  Goa  Brazil  Topicals –  Sikkim Ahme

  15. Slide 15: Pillars of Organisational Health

    Pillars of Organisational Health Continuous endeavour to improve overall organisation health in four key areas Creating value and Promoting Strengthening Enhancing bottom-up developing talent collaboration across accountability by innovation across the across the businesses and proper performance or

  16. Slide 16: Key Financial Numbers – FY 2013-14

    Key Financial Numbers – FY 2013-14 Consolidated (Rs. Mio.) Amount Gr.% Segment-wise Gross Sales Total Income from Operations 72,240 13.6% India Form., EBIDT 12,002 6.7% 34% EBIDT % to Income from Ops. 16.6% Profit before tax1 9,594 18.6% JVs, 6% PBT % to Income from Ops. 13.3% APIs, 5% Animal US, He

  17. Slide 17: Thank You.

    Thank You. Safe Harbour Statement This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also

Cadila Healthcare — Investor Presentation (August 2014) on 6ix